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Dermatomyositis is an inflammatory condition characterized by proximal muscle weakness and classic 
skin manifestations. The severity of these symptoms, however, can vary greatly. Here we present the 
case of a woman with a particularly severe form of the cutaneous signs. It is important to recognize 
the potential severity of this condition as the uncontrolled progression of this disease can lead to 
respiratory compromise and cardiac involvement. [Clin Pract Cases Emerg Med. 2019;3(3):222-225.]
INTRODUCTION
Dermatomyositis is an idiopathic, inflammatory 
condition characterized most commonly by proximal muscle 
weakness and a variety of skin manifestations.1 The hallmark 
dermatologic findings are Gottron’s papules and heliotrope 
eruptions, but the presence and severity of these findings can 
vary greatly and do not always correlate with other systemic 
symptoms.2-3 Described below is the case of a woman with 
a particularly severe exacerbation in the setting of recent 
medication cessation.
CASE REPORT
A 53-year-old female with a history of heart failure, 
chronic obstructive pulmonary disease, and biopsy-proven 
diagnosis of dermatomyositis presented to the emergency 
department (ED) with a one-week history of worsening 
shortness of breath, periorbital edema, diffuse pain, and 
intensely pruritic rash. She reported recent abrupt cessation 
of her prednisone due to concern for complications related 
to long-term steroid use to include lumbar spine fracture, as 
well as methicillin-resistant Staphylococcus aureus cellulitis 
that required intravenous (IV) antibiotics. Regarding her 
rash, she reported that it had been present since diagnosis of 
dermatomyositis in 2011; however, the rash had varied in 
intensity depending on medication regimen and compliance.
On arrival, the patient was in moderate distress secondary 
to pain but was speaking in full sentences. On presentation her 
vital signs were as follows: afebrile at 98.4 degrees Fahrenheit, 
tachycardic to 108 beats per minute, respiratory rate 18 beats 
per minute, oxygen saturation 100% on room air, blood 
pressure 138/73 millimeters of mercury, and reported 10/10 
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pain diffusely, but worse on face and scalp. Physical exam was 
significant for severe rash with erythematous and violaceous 
macules and patches of excoriation and lichenification over her 
scalp, face, neck, chest, abdomen, back, and on dorsal surface 
of arms, with the worst areas on her scalp (Image). Her exam 
was notable for severe excoriations of the scalp resulting in 
serosanguinous drainage. There was significant periorbital 
Image. Severe excoriations and rash over upper chest, scalp, and 
arm respectively.
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What do we already know about this clinical entity? 
Dermatomyositis is an autoimmune condition with 
a wide spectrum of severity. Most treatments only 
manage symptoms, attempt to slow the progression, 
and prevent complications.
What makes this presentation of disease reportable? 
We present a case of dermatomyositis of particular 
severity that demonstrates the importance of helping 
patients overcome obstacles to compliance.
What is the major learning point? 
Dermatomyositis, in severe cases, can produce 
significant scarring, pain, and risk of infection.
How might this improve emergency medicine 
practice? 
Providers need to recognize the spectrum of 
presentations, enabling us to both treat exacerbations 
and provide education and follow-up to help patients 
long-term.
edema resulting in difficulty opening her eyes voluntarily. 
The skin on her arms was sclerosed, making it difficult to 
obtain dependable vascular access, eventually necessitating 
placement of a central venous catheter in her right internal 
jugular. She had mild contractures at both elbows bilaterally 
and was unable to fully extend her arms. Her lower extremities 
were notable for 1+ non-pitting edema to her knees. Her 
abdomen was soft and non-tender, and although the rash was 
present on her abdomen, the skin was not as sclerosed as the 
scalp, face, and extremities. The rest of her physical exam was 
relatively normal with clear lung sounds, no abnormal heart 
sounds, and an unremarkable neurological exam.
The patient was given 125 milligrams IV 
methylprednisolone, one liter (L) bolus of normal saline, and 
pain control medication. Laboratory results revealed alkaline 
phosphatase 246 international units per liter (IU/L), B-type 
natriuretic peptide 585 picogram/milliliter, hemoglobin 
7.8 grams per deciliter, hematocrit 26.9%, and erythrocyte 
sedimentation rate 54 millimeters per hour. The remaining 
laboratory values were as detailed in the Table.
The patient was admitted and remained in the hospital for 
seven days. She received a course of IV steroids, and we obtained 
repeat punch biopsies. The biopsies demonstrated thickening of 
the basement membrane with dermal fibrosis, superficial vascular 
ectasia, and underlying septal-predominant panniculitis – features 
consistent with dermatomyositis. Dermatology and rheumatology 
follow-up appointments were made for the patient prior to 
discharge, but as of writing this report the patient had not kept 
her appointments and was not answering phone calls. Attempts 
are still being made to contact this patient for follow-up and 
continuation of treatment.
DISCUSSION
According to a database review study out of Ontario, 
Canada, only 3.3% of ED visits over a five-year period 
presented with a primary dermatologic complaint – 
approximately half of which were for a soft tissue infection 
rather than autoimmune pathologies. Of that 3.3%, only 4% 
required inpatient admission, making severe dermatologic 
conditions a relatively rare occurrence in the ED.4
When evaluating patients who present to the ED 
with a diffuse rash such as found in this case, many other 
conditions must be considered. Patients with systemic 
lupus erythematosus (SLE) can also present with facial 
erythema and photosensitive eruptions. SLE, however, 
will often spare the nasolabial folds and lacks the 
pronounced muscular involvement classically seen with 
dermatomyositis.5 Scalp dermatomyositis can also appear 
similar to cutaneous findings seen in psoriasis. However, 
psoriasis does not exhibit the poikilodermatous changes 
typically present in dermatomyositis, a characteristic 
exemplified in the case presented here.6 One must also 
consider infectious etiologies or, of more concern, 
a bacterial infection superimposed on a pre-existing 
autoimmune rash. In this case, while it was impossible to 
differentiate erythema caused by her chronic skin condition 
from erythema that could indicate infection, there were no 
other findings concerning for a concurrent infection (i.e., 
leukocytosis, fever, hypotension).
Dermatomyositis is a rare condition that affects an 
estimated two in 100,000 annually in the general population 
and has a 2:1 female predominance.7 The exact pathogenesis is 
not fully understood, but much of the literature demonstrates 
type 1 interferons and/or antibody and complement mediated 
damage to myofibrils and capillaries.8-10 Research into the 
development of the condition is made difficult by the low 
incidence of the disease. The paucity of large, randomized 
control studies makes standardized, targeted therapy especially 
difficult; most treatment regimens still focus on high-dose 
glucocorticoids and immunosuppressants. 
Contributing to the confusion surrounding the disease 
is the variable expression of symptoms among patients. 
The severity of the rash will vary from Gottron’s papules 
to a generalized erythroderma with variation presumably 
attributed to protective factors, genetic allotypes, and how 
quickly treatment was initiated after diagnosis.11-12 Clinical 
features that have been associated with a worse outcome 
include the following: delay in initiation of treatment for 
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Lab Result
Complete blood count
 White blood cell 7.35 K/mcL
 Hemoglobin 7.8 g/dL
 Hematocrit 26.9 %
 Platelets 469 K/mcL
Complete metabolic panel
 Sodium 137 mmol/L
 Potassium 3.2 mmol/L
 Chloride 102 mmol/L
 Carbon dioxide 30 mmol/L
 Blood urea nitrogen 7 mg/dL
 Creatinine 0.38 mg/dL
 Glucose 132 mg/dL
Liver
 Aspartate aminotransferase 48 U/L
 Alanine aminotransferase 19 U/L
 Alkaline phosphatase 246 U/L
 Bilirubin (total) 0.6 mg/dL
 Albumin 2.0 g/dL
Cardiac
 B-type natriuretic peptide 585 pg/ml
 Troponin <0.030 ng/ml
Other
 Creatine kinase 53 U/L
 Lactic acid 1.6 mmol/L
 Lipase 259 U/L
 Erythrocyte sedimentation rate 54 mm/hr
K/mcL, thousands per microliter; g/dL, grams per deciliter; mmol/L, 
millimoles per liter; mg/dL, milligram per deciliter; U/L, units per liter; 
pg/ml, picograms per milliliter; ng/ml, nanograms per milliliter; mm/hr, 
millimeter per hour.
Table. Initial laboratory results for patient with dermatomyositis.
more than six months after onset of symptoms; significant 
muscular weakness at presentation; dysphagia; respiratory 
muscle weakness; interstitial lung disease; cardiac 
involvement; and associated malignancy.13-17 Despite the 
need for more information and the variable presentation, 
increased recognition and rapid initiation of treatment has 
led to an increased rate of remission and an improved five-
year mortality for these patients. From 1971 to 1985, the 
five-year survival rate for inflammatory myopathies was 
52-65%, but improved to 75-95% in studies from 2001 to 
2006. Among the causes of death in this population, the most 
common are malignancies, infection, respiratory failure, and 
cardiovascular disease.18
The case of the patient presented here was a 
particularly serious one. Of the known features associated 
with poor prognosis, our patient demonstrated almost all of 
them. While she seemed to have been started on treatment 
soon after diagnosis in 2011, she had, at best, intermittent 
treatment due to long periods of non-compliance. Muscular 
weakness was not a predominant feature at the time of 
this presentation, but the presence of contractures in her 
bilateral upper extremities and a documented history of 
proximal upper extremity weakness were concerning for 
a poor prognosis. She also had a documented history of 
dysphagia with repeated neurologic evaluation. These 
factors combined with her existing comorbidities placed 
her at significant risk for poor outcome.
CONCLUSION
Dermatomyositis is a rare, incompletely-understood 
condition that presents with characteristic cutaneous findings. 
The patient discussed here presented with a severe form of 
the rash. It is likely that the severity of her condition was due 
in significant part to poor compliance and other social issues 
that prevented her from participating in treatment. Given 
the wide spectrum of severity seen in dermatomyositis, 
there remains much work to discover effective, affordable 
treatment. While not a common occurrence in the ED, it 
is still of vital importance for emergency physicians to 
recognize dermatomyositis exacerbations when they present. 
Given that it is a progressive disease, delays in treatment 
or misdiagnosis can lead to devastating changes that affect 
quality of life (scarring, expensive therapies, etc.), and can 
increase risk of death.
Documented patient informed consent and/or Institutional Review 
Board approval has been obtained and filed for publication of this 
case report.
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